Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

• Published in: Clinical pharmacology and therapeutics Vol. 113; no. 6; pp. 1258 - 1267
• Main Authors: Gueorguieva, Ivelina, Willis, Brian A., Chua, Laiyi, Chow, Kay, Ernest, C. Steven, Shcherbinin, Sergey, Ardayfio, Paul, Mullins, Garrett R., Sims, John R.
• Format: Journal Article
• Language: English
• Published: United States 01.06.2023
• Subjects: Alzheimer Disease - drug therapy; Amyloid beta-Peptides; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Heterozygote; Humans; Plaque, Amyloid - drug therapy

Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER‐ALZ study (NCT03367403). The objectives of the current analyses are to characterize (i) the population pha...